## Osteoporosis International

**COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY**

--Manuscript Draft--

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>OSIN-D-13-00312R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Original Article</td>
</tr>
</tbody>
</table>
| Abstract:          | Purpose: The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from antero-posterior spine DXA scans. The potential role of TBS for monitoring treatment response with bone active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

Methods: Two patient groups with matched age, BMI, and baseline LS BMD, treated with either daily subcutaneous teriparatide (N=65) or quarterly intravenous IBN (N=122) during 2 years and with available LS BMD measurements at baseline and two years after treatment initiation were compared.

Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age, 67.9± 7.4 years; body mass index, 23.8 ± 3.8 kg/m2; BMD L1-L4, 0.741 ± 0.100 g/cm2 and TBS, 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. +0.3% ± 4.1, respectively; p < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r² = 0.04) with no correlation between the changes in BMD and TBS over 24 months.

Conclusions: In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

KEY WORDS: osteoporosis, parathyroid hormone, teriparatide, bone mineral density, trabecular bone score, treatment, open-label study |

<table>
<thead>
<tr>
<th>Corresponding Author:</th>
<th>Kurt Lippuner, M.D. University Hospital and University of Berne Bern, SWITZERLAND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corresponding Author Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Corresponding Author's Institution:</td>
<td>University Hospital and University of Berne</td>
</tr>
<tr>
<td>Corresponding Author's Secondary Institution:</td>
<td></td>
</tr>
<tr>
<td>First Author:</td>
<td>Christoph Senn</td>
</tr>
<tr>
<td>First Author Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Order of Authors:</td>
<td>Christoph Senn Beatrice Günther Albrecht W Popp</td>
</tr>
</tbody>
</table>
Dear Prof Seeman

please find herewith the revised manuscript. We hope that it will be acceptable for publication in OI in its present form.

With best regards,
Kurt Lippuner

OSIN-D-13-00312R1
"COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY"

Reply to reviewers' comments:

Thank you for having reviewed and commented our work. You will find our reply (bold fonts) to your questions / comments / suggestions (normal fonts) below. These reconcile with changes to the manuscript also highlighted in bold fonts directly in its text.

Reviewer #1:

The authors compared the effect of treatment for 2 years with Teriparatide (TPTD) or Ibandronate (IBN) on BMD lumbar spine and TBS (trabecular bone score) in 187 postmenopausal women with osteoporosis. The study was retrospective, non-randomised and open-label. The patients were matched for age, BMI, BMD and TBS but not for osteoporosis severity evaluated by previous fractures, previous BP-treatment and FRAX score. BMD and TBS were not able to discriminate patients with more severe osteoporosis from patients with less severe osteoporosis. Patients treated with TPTD responded with larger increases in BMD and TBS than the patients treated with IBN. There was no correlation between BMD and TBS at baseline or between the changes in the two parameters with treatment.

Specific comments:

Material and methods:

p.6, l.9-: It should be stated that the study design is retrospective, non-randomised and open-label. It should be stated that study compares the effects of up to 2-years treatment with TPTD with 2-years treatment with IBN.

The first paragraph has been amended as follows: “The study was conducted at the Department of Osteoporosis of the University Hospital of Berne, Switzerland as an open-label, retrospective, non-randomised, treatment-controlled study comparing the effects of an up to 2-year treatment with subcutaneous teriparatide (Forsteo®, Eli Lilly, USA) vs. a 2-year treatment with intravenous IBN (Boniva®, Roche, Switzerland) on LS BMD and TBS in two groups of postmenopausal women with osteoporosis matched for age, BMI, and LS BMD.”

Furthermore, if DXA at baseline and after two years only was available in 65 and 122 patients in the two groups, respectively and this is one of the inclusion criteria, then only these patients can be included in the study. The authors may have evaluated 70 and 140 patients, respectively, to include these patients. This needs clarification in the manuscript.

To avoid any confusion, the word “eligible” was replaced by “evaluated” in the study population section of the methods. In addition, the following sentence was added as a final sentence in the same paragraph: “Only women with evaluable DXA scans for both LS BMD and TBS at baseline and after two years in the teriparatide and the
ibandronate groups, respectively, were included in the analysis."

Figure 1: If TPTD patients were only treated for on average 22.9 months with TPTD, information about the follow-up treatment should be provided. The legend of figure 1 was amended as follows: “Percent change in lumbar spine BMD and TBS at month 24 after treatment with teriparatide (22.9 months) and ibandronate (24 months). Mean values ± standard deviation p values above the bars refer to significance vs. baseline.”

In addition, the following clarifying sentence was added to the methods section / study population and treatment schemes:

“The reimbursed duration of treatment with teriparatide was increased from 18 to 24 months during the course of the study. As a consequence, one sixth of the patients treated with teriparatide were treated during 18 months followed by an intravenous infusion of zoledronate 5mg, the other five sixths were on teriparatide during 24 months.”

Results:

p.9 and figure 1: As the interesting results are the changes and the variation in the changes in the two groups of patients and not the group mean changes, the changes should be presented as mean±SD in the text as well as in the figure. The changes as the two hip sites mentioned in table 1 should also be provided. As requested, the SEM on figure 1 have been replaced by SD, consistent with the text. Regarding the hip results, the aim of the study was to have a head to head skeletal site matched comparison between spine BMD and TBS for the two treatments. We feel that providing hip results in this paper would dilute the message, even more so if results were to be added to figure 1. Thus, we suggest not mentioning the hip results in the manuscript. For your personal information the total hip and FN BMD increased by +0.12±4.5% and +0.44±5.0% for the PTH group and by +2.5±3.5% and +0.5±4.5% for the IBN group, respectively. As already stated, we recommend not adding this information to the manuscript but may of course do so on your request.

Table 2: As LSCs are 2.49% and 3.10% it is clear what above and below LSC mean, but not what within LSC means?
Within LSC means, all values comprised between +2.49 and −2.49% and between +3.10 and +3.10% for spine BMD and TBS, respectively. We have clarified this confusing point by adding a corresponding footnote to table 2.

Reviewer #2:

The Authors have replied to my comments. I have no further remarks.

Thank you for your comments and suggestions which greatly contributed to improving the quality of our work.
COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS) IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. A 2-YEAR OPEN-LABEL STUDY

Christoph Senn¹, Beatrice Günther¹, Albrecht W Popp¹, Romain Perrelet¹, Didier Hans²*, Kurt Lippuner¹**

¹ Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, 3010 Berne, Switzerland
² Center of Bone Disease, Bone and Joint Department, Lausanne University Hospital, Avenue Pierre Decker 4, 1011 Lausanne VD, Switzerland
* co-directed equally the TBS study

Corresponding author:

Kurt Lippuner, M.D.
Chairman and Head
Department of Osteoporosis
Inselspital, Berne University Hospital
and University of Berne
CH-3010 Berne
Switzerland
phone  +41 31 632 31 28
fax  +41 31 632 03 28
email  kurt.lippuner@insel.ch
ABSTRACT (words = 246)

Purpose: The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from antero-posterior spine DXA scans. The potential role of TBS for monitoring treatment response with bone active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

Methods: Two patient groups with matched age, BMI, and baseline LS BMD, treated with either daily subcutaneous teriparatide (N=65) or quarterly intravenous IBN (N=122) during 2 years and with available LS BMD measurements at baseline and two years after treatment initiation were compared.

Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age, 67.9± 7.4 years; body mass index, 23.8 ± 3.8 kg/m²; BMD L1-L4, 0.741 ± 0.100 g/cm² and TBS, 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. +0.3% ± 4.1, respectively; p < 0.001 for both). LS BMD and TBS were only weakly correlated at baseline (r² = 0.04) with no correlation between the changes in BMD and TBS over 24 months.

Conclusions: In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

KEY WORDS: osteoporosis, parathyroid hormone, teriparatide, bone mineral density, trabecular bone score, treatment, open-label study

MINI ABSTRACT

Treatment effects over two years of teriparatide versus ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine BMD and trabecular bone score (TBS).
Teriparatide induced larger increases in BMD and TBS compared to ibandronate suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.
INTRODUCTION:

Osteoporosis and osteoporosis-related fractures represent a worldwide disease burden, especially in North America and Europe [1-5]. With much of this burden stemming from the morbidity and mortality related to the roughly nine million osteoporotic fractures that occur each year [4, 5], the primary goal of treatment has long been fracture prevention [6-8].

As recommended by the World Health Organization (WHO) since 1994 [9], bone mineral density (BMD), measured by dual x-ray absorptiometry (DXA), is the current gold standard for diagnosing osteoporosis and monitoring treatment, supported by the fact that BMD is a major determinant of bone strength and fracture risk [10]. However, considerable overlap exists between BMD values in individuals who develop fractures and those who do not [11], indicating that other factors influence both bone strength and fracture risk. To cite just but a few: macro-geometry of cortical bone, micro-architecture of trabecular bone, as well as bone micro-damage, mineralization, and turnover [12-14].

The trabecular bone score (TBS) is derived from a simple antero-posterior LS DXA scan and can be used for the non-invasive assessment of intravertebral cancellous bone microarchitecture [15-18]. The TBS was shown to discriminate between patients with incident hip, non-vertebral or vertebral fracture and non-fractured patients with osteoporosis in several prospective and retrospective cohort studies [19-24], with odds ratios ranging between 1.6 and 2.05 with a similar order of magnitude than lumber spine BMD [19, 21, 22, 24]. In addition, in these studies, the combination of TBS and lumbar spine BMD (LS BMD) was generally superior to either measurement alone with regard to fracture risk prediction [19, 20, 22-24]. Furthermore, the TBS was responsive to treatment with antiresorptive drugs in a large cohort study [25] and in the retrospective analysis of a randomized placebo-controlled trial with the aminobisphosphonate zoledronate [26].
Daily subcutaneous injections of recombinant human 1-34 N-terminal fragment of parathyroid hormone (teriparatide) were shown to increase BMD and to reduce the risk of new vertebral and non-vertebral, but not hip, fractures in patients with postmenopausal and glucocorticoid-induced osteoporosis [27, 28]. The observed increases in LS BMD with teriparatide accounted for approximately 30-41% of the achieved vertebral fracture risk reduction, suggesting other mechanisms accounting for the remainder [27, 29]. Teriparatide was recently shown to improve trabecular microarchitecture in iliac crest bone biopsies of postmenopausal women [29], confirming earlier preclinical data showing improved histomorphometric cancellous bone parameters and vertebral bone strength in ovariectomized rats [30] and monkeys [31]. The effects of teriparatide on the TBS are unknown.

Bisphosphonates, such as the aminobisphosphonate ibandronate (IBN), are inhibitors of bone resorption belonging to the mainstay of osteoporosis treatment. Histomorphometric data in postmenopausal women treated during two years with intravenous ibandronate showed no increase in trabecular number or volume and no decrease in inter-trabecular separation [32]. In line with these findings, an earlier study performed with the intravenous aminobisphosphonate zoledronate in postmenopausal women showed an only modest increase in TBS consistent with a preservation of vertebral bone micro-architecture [26].

The aims of this study were: (1) to compare the effects of subcutaneous teriparatide and intravenous ibandronate on LS BMD and TBS in postmenopausal women with osteoporosis; (2) to assess whether the changes in TBS are independent of those of BMD; and (3) to evaluate the changes in TBS in terms of possible clinical relevance at the individual patient level.
MATERIALS AND METHODS:

The study was conducted at the Department of Osteoporosis of the University Hospital of Berne, Switzerland as an open-label, retrospective, non-randomised, treatment-controlled study comparing the effects of an up to 2-year treatment with subcutaneous teriparatide (Forsteo®, Eli Lilly, USA) vs. a 2-year treatment with intravenous IBN (Bonviva®, Roche, Switzerland) on LS BMD and TBS in two groups of postmenopausal women with osteoporosis matched for age, BMI, and LS BMD.

Study population and treatment schemes

Postmenopausal women with primary osteoporosis referred for evaluation to the osteoporosis consultation of the Department of Osteoporosis of University Hospital of Berne, Switzerland, between 2007 and 2009 who were subsequently treated with teriparatide 20μg self-injected daily were evaluated if they had LS BMD measurements performed by DXA at baseline and after 2 years of therapy (n=70). Women treated with teriparatide usually had experienced a vertebral fragility fracture during a prior therapy with an antiresorptive, independently of their LS BMD value. The reimbursed duration of treatment with teriparatide was increased from 18 to 24 months during the course of the study. As a consequence, one sixth of the patients treated with teriparatide were treated during 18 months followed by an intravenous infusion of zoledronate 5mg, the other five sixth were on teriparatide during 24 months. The control group consisted of postmenopausal women with primary osteoporosis in whom a treatment with intravenous ibandronate 3mg every 3 months was initiated between 2007 and 2009 and monitored during at least two following years at the Department of Osteoporosis of Berne. Women treated with ibandronate usually had a BMD T-score at or below -2.5 or one or more prevalent vertebral fractures. Women on ibandronate were matched for age, BMI, and LS BMD with women in the teriparatide group, following a 2:1 ratio (n=140). All subjects were vitamin D-replete and received adequate calcium and vitamin D3
supplementation. Women currently on glucocorticoids or presenting other secondary forms of osteoporosis were not eligible. Prior therapies with bisphosphonates, estrogens, or other bone active substances, including vitamin D were allowed. Only women with evaluable DXA scans for both LS BMD and TBS at baseline and after two years in the teriparatide and the ibandronate groups, respectively, were included in the analysis.

**Measurement of bone mineral density (BMD)**

Bone mineral density was assessed by DXA (Hologic QDR 4500A®, Hologic, Bedford, MA, USA) at the single study centre of the Department of Osteoporosis of the University Hospital of Berne, Switzerland. All DXA scans were performed in accordance with manufacturer recommendations. Lumbar spine BMD measurements were recorded for L1 through L4 (L1-4). BMD was expressed as grams per square centimeter of hydroxyapatite and as T-scores (standard deviation [SD] from the mean of a healthy young female population). The manufacturer’s normative database was used as reference for the LS after analysis according to International Society for Clinical Densitometry (ISCD) rules [33]. Individual vertebrae were excluded in case of fractures or degenerative changes, in accordance with ISCD rules for individual vertebrae exclusion (more than 1 standard deviation from immediately adjacent vertebrae). Quality control was performed daily (anthropometric spine phantom supplied by the manufacturer).

**Measurement of trabecular bone score (TBS)**

The trabecular bone score (TBS) is a grey-level texture measurement that can be applied to DXA images for quantifying local variations in grey level [15-17]. Using experimental variograms of 2D projection images, TBS can differentiate between 3-dimensional (3D) micro-structures that exhibit the same bone density, but different trabecular characteristics [15, 18]. The TBS is obtained by direct (re-)analysis of an acquired lumbar spine DXA image.
without need for further imaging. All TBS determinations were performed in a blinded manner within the Bone Disease Unit at the University Hospital of Lausanne, Lausanne, Switzerland using TBS iNsight® Software version 1.8.2 (Med-Imaps, Bordeaux, France). Lumbar spine TBS (LS TBS) was evaluated in the same vertebrae and regions of measurement as those used for LS BMD, with LS TBS calculated as the mean value of the individual measurements for vertebrae L1-L4. The coefficient of variation for LS BMD measurements at the Department of Osteoporosis of the University Hospital of Berne is 0.90% when applying with ISCD recommendations (15 outpatients representative of our daily routine with triplicate measurements after repositioning) with a corresponding coefficient of variation of 1.12% for TBS. Thus, the Least Significant Change (LSC) is 2.49% for LS BMD and 3.10% for TBS.

Statistical analysis

Descriptive analysis included means and percentages with standard deviations. The percent changes in BMD and TBS were calculated for each subject as the absolute change from baseline to two-year follow-up, divided by the baseline value. Bivariate inter-group comparisons were performed between those treated with IBN vs. teriparatide using Student’s t-tests and Pearson χ² analysis for continuous and non-continuous variables, respectively. Pearson correlation coefficients were calculated for BMD vs. TBS and for change from baseline in BMD vs. change from baseline in TBS. All inferential tests were two-tailed and p < 0.05 was set as the threshold for statistical significance. All statistical analyses were performed using Stata® software (Version 12, StataCorp LP., Texas, USA).

RESULTS

Overall, 65 (93%) and 122 (87%) patients with evaluable DXA scans for LS BMD and TBS at baseline and after two years in the teriparatide and the ibandronate groups, respectively,
were included in the analysis. In total, 40%, 40%, and 20% of the patients had 4, 3, and 2 vertebrae evaluated, respectively. As a result of matching, baseline characteristics (mean ± SD) were similar between groups in term of age, body mass index, baseline LS BMD T-score and LS TBS (Table 1). Patients in the teriparatide group were more likely having had prior therapy with a bisphosphonate (95.4% vs. 80.3%, p=0.005), having prevalent vertebral fractures or a positive history of fracture during adulthood (90.5% vs. 44.3% and 73.8% vs. 41.0%, respectively; p=0.0001 for both), and had a significantly higher clinical fracture risk score for hip and major osteoporotic fractures assessed by FRAX®.

As shown in figure 1, after 24 months of therapy, LS BMD and TBS increased significantly more with teriparatide compared to IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. +0.3% ± 4.1, respectively; p < 0.0001 for both). Compared to baseline, increases in LS BMD were significant in both the teriparatide and IBN group (p<0.0001 for both) while increases in LS TBS were significant in the teriparatide group only (p< 0.0001).

Baseline spine BMD and TBS were only weakly correlated, (r² = 0.04), indicating that only 4% of the variance in one parameter was explained by the other. There was no correlation between the 2-year changes in BMD and TBS from baseline (r² = 0.01).

As shown in table 2, LS BMD was more sensitive than LS TBS with regard to the proportion of patients achieving an increase above least significant change (LSC) in both treatment groups: 78.5% vs. 61.5% (McNemar-test p<0.01) and 51.6% vs. 26.3% (p<0.001) with teriparatide and IBN, respectively. Interestingly, while only 11.0% of the patients did not respond in terms of TBS below the LSC with teriparatide, this proportion reached 27.0% with IBN. Furthermore, in the teriparatide group, 51.0% of the patients were above the LSC for both LS BMD and TBS vs. only 28.0% in the IBN group (results not shown in table 2), suggesting a stronger effect on bone micro-architecture with the former than with the latter.

DISCUSSION
In postmenopausal women with primary osteoporosis, a 2-year treatment with teriparatide increased LS BMD and TBS significantly more and in a significantly greater proportion of patients than a 2-year treatment with intravenous ibandronate. As the increase in LS TBS was largely independent from the BMD response, these results suggests that LS TBS may contribute to assess the effects of bone anabolic agents on vertebral micro-architecture.

Only few studies have investigated the effect of bone active substances on LS TBS [25, 26]. Taken together with the present findings, these earlier reports are consistent with the concept that bisphosphonates allow for “positive maintenance” of bone micro-architecture rather than a major improvement in micro-architecture. For almost two decades, bisphosphonates have been the therapy of choice to treat osteoporosis and to prevent fractures, relying on solid evidence with regard to fracture risk reduction [2, 34-38]. However, the long-term bone safety of bisphosphonates has been recently questioned [39]. On one hand, bisphosphonates increase bone strength by increasing the mineralization of remodelled bone units, reducing cortical porosity and decreasing focal stress. On the other hand, they suppress the generation of new bone remodelling units and reduce bone turnover [39]. In the present study, the increase in LS BMD and TBS observed with IBN was of a lower order of magnitude than expected. In earlier studies, LS TBS increased by 0.25 to 0.5% per year under antiresorptive therapy [25, 26], which is clearly more than the 0.3% over two years reported in the present study. One of the possible explanations may be related to the fact that more than 80% of the “real life” women included had been on bisphosphonate therapy before being switched to intravenous ibandronate after a very short or no washout period. This suggests not unexpectedly that, in patients under prior antiresorptive therapy, bisphosphonates may be more likely to maintain than to restore vertebral microarchitecture.
Teriparatide exerts primarily bone anabolic effects, which include increasing cancellous bone volume and connectivity, increasing cortical bone thickness, and enhancing trabecular morphology [39, 40]. Since the inaugural publication by Neer et al in 2001 [27], several smaller studies have confirmed that teriparatide allows for strong BMD increases and for fracture risk reduction, suggesting that it may become an attractive alternative to bisphosphonates for strengthening and possibly restoring bone microarchitecture [41-44]. In the present study, a 2-year therapy with subcutaneous teriparatide induced a statistically significant increase in LS BMD and TBS of large magnitude. The latter (+4.3% in only two years) exceeds by far the TBS increases reported with antiresorptive substances to date [25, 26]. Furthermore, the ratio of BMD to TBS increase was approximately 2:1 with teriparatide and 9:1 with ibandronate in the present study, compared to 10:1 with bisphosphonates in a retrospective study of 534 postmenopausal women treated with antiresorptive therapy in the Canadian province of Manitoba [25], and 4:1 in a 3-year randomized controlled study with yearly intravenous zoledronate [26]. Taken together with the absence of a significant correlation between changes from baseline in BMD and changes from baseline in TBS [25, 26], these observations indicate that BMD and TBS measure different characteristics of bone and bone strength.

With regard to individual therapy monitoring, only 12-35% of patients on bisphosphonates had an increase in TBS that was exceeding the LSC in earlier studies [25, 26], as compared to 26% in the present analysis. In contrast, about 62% of the patients on teriparatide were above LSC, primarily indicating that LS TBS may be more suitable for monitoring the effects of bone anabolic substances than for monitoring the effects of antiresorptives.

To date, only one direct comparison between teriparatide and a bisphosphonate (risedronate) has been published in postmenopausal women with osteoporotic spine compression fractures.
In that study, teriparatide yielded a significantly greater increase in BMD from baseline in the lumbar spine and femoral neck, and was associated with a lower incidence of vertebral fractures at 18 months (4% versus 9%, respectively; p = 0.01) and with less severe vertebral fractures (p = 0.04) [45]. There have, on the other hand, been several studies assessing the effects of teriparatide in patients in whom bisphosphonate treatment has failed or otherwise been terminated. In the most recently-published study, post-menopausal women with severe osteoporosis who had failed treatment with a bisphosphonate responded well to 18 months of treatment with daily parathyroid hormone, with a 37% reduction in the incidence of fractures in their second year of treatment relative to their first 6 months of therapy, and a 76% reduction relative to baseline subsequent to this. Patients also reported reduced back pain and improved health-related quality of life while taking teriparatide [46]. These results are consistent with the results of several prior studies demonstrating some benefit of parathyroid hormones in the aftermath of bisphosphonate therapy [41, 44, 47] although it is the first time that results are reported with TBS.

The findings of the present study are limited by the retrospective nature of the analysis. Pretreatment with antiresorptives may have partially blunted some of the expected effects on LS BMD and TBS. In addition, the two groups were not comparable with respect to osteoporosis severity, which may have influenced the results. Keeping these limitations in mind, the results show for the first time that larger effects on trabecular microarchitecture assessed by TBS may be expected when using bone anabolic substances and may open the way for future research in this direction including, but not limited to, the place of TBS alone and/or in combination with BMD and/or clinical risk factors for the choice and monitoring of treatments with bone active substances and the identification of more individualized treatment schemes for patients with osteoporosis at increased risk of fracture.

CONCLUSIONS
In women with postmenopausal osteoporosis, a 2-year treatment with teriparatide exerted more beneficial effects on lumbar spine BMD and microarchitecture assessed by TBS than ibandronate. Changes in LS BMD and TBS from baseline were not correlated, confirming that these two parameters measure different responses of bone to therapy. At the individual patient level, TBS was significantly more sensitive to bone anabolic substances than to antiresorptives, with almost two thirds of the patients on teriparatide showing TBS increases above the least significant change.
Figure legends

Figure 1

Percent change in lumbar spine BMD and TBS at month 24 after treatment with teriparatide (22.9 months) and ibandronate (24 months).

Mean values ± standard deviation

p values above the bars refer to significance vs. baseline.
Disclosures

Didier Hans is co-owner of the TBS patent and has corresponding ownership shares.

Christoph Senn, Beatrice Günther, Albrecht W. Popp, Romain Perrelet and Kurt Lippuner declare that they have no conflict of interest.

Acknowledgements

We are grateful to Philippe Kress, MD, for reviewing and commenting on our manuscript.
References


17
Table 1: Baseline Demographics and Clinical Characteristics (mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>Teriparatide Group</th>
<th>IBN Group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>65</td>
<td>122</td>
<td></td>
</tr>
<tr>
<td>Duration of active treatment (months)</td>
<td>22.9 ± 3.6</td>
<td>24.0 ± 4.7</td>
<td>0.10</td>
</tr>
<tr>
<td>Age (years)</td>
<td>68.9 ± 9.0</td>
<td>67.4 ± 6.5</td>
<td>0.20</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.7 ± 4.2</td>
<td>23.8 ± 3.5</td>
<td>0.92</td>
</tr>
<tr>
<td>Prior therapy with an oral / IV bisphosphonate (%)</td>
<td>95.4</td>
<td>80.3</td>
<td>0.005</td>
</tr>
<tr>
<td>Duration of washout prior to study drug initiation (months)</td>
<td>0.23 ± 0.79</td>
<td>0.26 ± 0.85</td>
<td>0.23</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Teriparatide Group</th>
<th>IBN Group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMD (g/cm²)</td>
<td>0.759 ± 0.153</td>
<td>0.732 ± 0.080</td>
<td>0.12</td>
</tr>
<tr>
<td>T-score</td>
<td>-2.66 ± 1.35</td>
<td>-2.77 ± 0.67</td>
<td>0.46</td>
</tr>
<tr>
<td>TBS</td>
<td>1.206 ± 0.100</td>
<td>1.209 ± 0.100</td>
<td>0.85</td>
</tr>
<tr>
<td>Total hip</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMD (g/cm²)</td>
<td>0.703 ± 0.113</td>
<td>0.729 ± 0.100</td>
<td>0.10</td>
</tr>
<tr>
<td>T-score</td>
<td>-1.96 ± 0.93</td>
<td>-1.75 ± 0.78</td>
<td>0.11</td>
</tr>
<tr>
<td>Femoral neck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMD (g/cm²)</td>
<td>0.606 ± 0.105</td>
<td>0.622 ± 0.084</td>
<td>0.27</td>
</tr>
<tr>
<td>T-score</td>
<td>-2.09 ± 1.17</td>
<td>-2.11 ± 0.81</td>
<td>0.91</td>
</tr>
<tr>
<td>Prevalent vertebral fractures (%)</td>
<td>90.5</td>
<td>44.3</td>
<td>0.0001</td>
</tr>
<tr>
<td>Positive history of non-vertebral fractures during adulthood (%)</td>
<td>73.8</td>
<td>41</td>
<td>0.0001</td>
</tr>
<tr>
<td>Past use of glucocorticosteroids (%)</td>
<td>9%</td>
<td>4.6%</td>
<td>0.28</td>
</tr>
<tr>
<td>10-year absolute risk for major osteoporotic fractures (FRAX® with BMD, %)</td>
<td>26.7 ± 10.4</td>
<td>21.1 ± 10.1</td>
<td>0.0001</td>
</tr>
<tr>
<td>10-year absolute risk for hip fractures (FRAX® with BMD, %)</td>
<td>8.15 ± 6.7</td>
<td>5.1 ± 5.1</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

All values are means ± SD, except indicated otherwise.
Table 2: Percentage of patients above, within and below the least significant change (LSC) for both teriparatide and IBN groups and for lumbar spine (LS) BMD and TBS

<table>
<thead>
<tr>
<th></th>
<th>Above LSC (%)</th>
<th>Within LSC (%)</th>
<th>Below LSC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teriparatide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS BMD</td>
<td>78.5</td>
<td>20.0</td>
<td>1.5</td>
</tr>
<tr>
<td>LS TBS</td>
<td>61.5</td>
<td>27.7</td>
<td>10.8</td>
</tr>
<tr>
<td>Ibandronate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS BMD</td>
<td>51.6</td>
<td>42.6</td>
<td>5.8</td>
</tr>
<tr>
<td>LS TBS</td>
<td>26.3</td>
<td>46.7</td>
<td>27.0</td>
</tr>
</tbody>
</table>

Within LSC for LS BMD is between -2.49% and +2.49%
Within LSC for LS TBS is between -3.10% and +3.10%
Mean percent change over 24 months

- **Teriparatide**
  - Spine BMD: p < 0.0001
  - Spine TBS: p < 0.0001

- **Ibandronate**
  - Spine BMD: p < 0.0001
  - Spine TBS: p = 0.86
COMPARATIVE EFFECTS OF TERIPARATIDE AND IBANDRONATE ON SPINE BONE MINERAL DENSITY (BMD) AND MICROARCHITECTURE (TBS)

First Author: Senn C
E-mail: christoph.senn@insel.ch

After submission of this agreement signed by all authors, changes of authorship or in the order of the authors listed will not be accepted by Springer.

AUTHORSHIP
I, the undersigned author(s), certify that:
- I have seen and approved the final version of the manuscript, and all subsequent versions.
- I have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
- I have drafted the article or revised it critically for important intellectual content.

I accept public responsibility for it, and believe it represents valid work. As an author of this article, I also certify that none of the material in the manuscript has been previously published, nor is it included in any other manuscript. I certify that this manuscript is not under consideration for publication elsewhere, nor has it been submitted or accepted in another publication in any form. The rights or interest in the manuscript have not been assigned to any third party.

Moreover, should the editor of Osteoporosis International request the data upon which the manuscript is based, I shall produce it. I also certify that I have read and complied with the copyright information, as found on the Osteoporosis International home page website.

FINANCIAL DISCLOSURE/CONFLICT OF INTEREST
I certify that any financial interests such as employment, stock ownership, honoraria, paid expert testimony, as well as any personal relationships, academic competition, and intellectual passion which may inappropriately influence my actions, have been disclosed on a separate attachment.

All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged in a footnote.

I have had full access to all the data in the study (if applicable) and thereby accept full responsibility for the integrity of the data and the accuracy of the data analysis.

By checking the box next to my signature I assert that there are no conflicts of interest (both personal and institutional) regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.

PLEASE NOTE
1. Every author must sign the Authorship & Disclosure form.
2. It is possible to submit more than one form if the authors are in several locations.
3. All forms must be submitted at the same time.
4. Completed forms must be scanned and included as a pdf file during the online submission process as a supplemental file not for review.

Please email any queries to the appropriate Managing Editor:
European Office: Fina Liu – oi.europe@iofbonehealth.org
USA Office: Adrianne Tewksbury – tewksburya@helenhayeshosp.org
OSTEOPOROSIS INTERNATIONAL
Authorship & Disclosure Form

MANUSCRIPT ID NUMBER (IF KNOWN)

Author's signature
Christopher Seny
Printed name and date
20 Nov 2013

Author's signature
Beatrice Gauthier
Printed name and date
20 Nov 2013

Author's signature
Albrecht W. Papp
Printed name and date
20 Nov 2013

Author's signature
Romain Perrelet
Printed name and date
21 Nov 2013

Author's signature
Didier Hollis
Printed name and date
20 Nov 2013

Author's signature
Lippuner K., 20 Nov 2013

Author's signature

Printed name and date

Author's signature

Printed name and date

Author's signature

Printed name and date

Author's signature

Printed name and date

Author's signature

Printed name and date

Page 2 of 2- (signatures & dates required on page 2)